logo

CYBN

Cybin·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

CYBN fundamentals

Cybin (CYBN) released its earnings on Nov 13, 2025: revenue was -- (YoY 0.00%), beat estimates; EPS was -1.39 (YoY 0.00%), missed estimates.
Revenue / YoY
--
0.00%
EPS / YoY
-1.39
0.00%
Report date
Nov 13, 2025
CYBN Earnings Call Summary for Q2,2026
  • Clinical Momentum: CYB003 Phase III global expansion (330 pts) and CYB004 Phase II readout (1Q26) highlight late-stage pipeline strength.
  • Financial Strength: $175M financing secures 2026-2027 liquidity, with 70% allocated to CYB003 execution.
  • Operational Focus: Real-world clinic workflow design (short sessions, no new infrastructure) and durability (12-month remission data) differentiate psilocin.
  • CEO Search: Seeking leader with commercialization, big pharma, and capital management expertise.
EPS
Revenue

Revenue & Expenses

Key Indicators

Cybin (CYBN) key financial stats and ratios, covering profitability, financial health, and leverage.
Cybin (CYBN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Cybin (CYBN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Cybin (CYBN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Cybin (CYBN) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Cybin (CYBN) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield